Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOMARIN PHARMACEUTICAL INC.

(BMRN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Biomarin Pharmaceutical Inc. Announces Executive Changes

02/03/2020 | 04:32pm EST

BioMarin Pharmaceutical Inc. announced that effective January 29, 2020, Dan Spiegelman had transitioned from serving as the Company’s Executive Vice President and Chief Financial Officer. Mr. Spiegelman will remain with BioMarin as an employee and senior advisor until September 1, 2020 (the “Separation Date”) to assist with the transition. After that, he plans to pursue other interests and spend more time with family. Also on January 29, 2020, Brian Mueller, BioMarin’s Senior Vice President, Finance and Chief Accounting Officer assumed the roles of acting Chief Financial Officer and principal financial officer, in addition to his responsibilities as principal accounting officer, while the Company conducts an internal and external search for the role of Chief Financial Officer. Mr. Mueller joined BioMarin in December 2002 and currently serves as the Company’s Senior Vice President, Finance and Chief Accounting Officer in addition to his role as acting Chief Financial Officer. He has served as BioMarin’s Chief Accounting Officer since March 2011. From March 2014 to August 2016, Mr. Mueller served as the Company’s Group Vice President, Corporate Controller and from March 2009 to March 2014, Mr. Mueller served as the Company’s Vice President, Corporate Controller. Mr. Mueller is a member of the board of Directors of Anthera Pharmaceuticals Inc., a biopharmaceutical company where he also served as Chairman of the Audit Committee. Prior to joining BioMarin in 2002, Mr. Mueller worked for KPMG as a senior manager in the firm’s audit practice. Mr. Mueller joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firm’s audit and business advisory services practice.


© S&P Capital IQ 2020
All news about BIOMARIN PHARMACEUTICAL INC.
11/30BIOMARIN TO HOLD VIRTUAL R&D DAY AT : 00am ET Today
PR
11/29BioMarin to Participate in Two Upcoming Virtual Investor Conferences
PR
11/23INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against ..
BU
11/22INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Bio..
BU
11/22Credit Suisse Raises BioMarin Pharmaceutical's PT to $105 from $100 After VOXZOGO Gets ..
MT
11/22Goldman Sachs Adjusts Price Target for BioMarin Pharmaceutical to $173 From $169, Maint..
MT
11/22Baird Adjusts Price Target for BioMarin Pharmaceutical to $112 From $101, Maintains Out..
MT
11/22JPMorgan Adjusts BioMarin Pharmaceutical's Price Target to $135 From $129, Maintains Ov..
MT
11/22Morgan Stanley Adjusts Price Target on BioMarin Pharmaceutical to $90 From $82, Maintai..
MT
11/22SVB Leerink Adjusts BioMarin Pharmaceutical's Price Target to $115 from $112, Keeps Out..
MT
More news
Analyst Recommendations on BIOMARIN PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2021 1 842 M - -
Net income 2021 -67,5 M - -
Net cash 2021 109 M - -
P/E ratio 2021 -229x
Yield 2021 -
Capitalization 15 466 M 15 466 M -
EV / Sales 2021 8,34x
EV / Sales 2022 7,08x
Nbr of Employees 3 059
Free-Float 99,4%
Chart BIOMARIN PHARMACEUTICAL INC.
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 84,24 $
Average target price 115,35 $
Spread / Average Target 36,9%
EPS Revisions
Managers and Directors
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive Vice President
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. von Pervieux Chief Information Officer
Lon Cardon Chief Scientific Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOMARIN PHARMACEUTICAL INC.-3.93%15 466
CSL LIMITED4.63%95 165
WUXI BIOLOGICS (CAYMAN) INC.-6.71%52 197
SAMSUNG BIOLOGICS CO.,LTD.9.08%50 476
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.55%32 920